If you are a woman with migraines, there's a good chance you get some of them around the time of your period. These migraines are called Menstrual Migraine. In fact, Menstrual Migraine usually occurs two days before your period starts and up to the third day of your period.

Use our three-month tracker to mark down symptoms when they occur. Record when you first notice the symptoms of your migraine attack as well as the headache pain and its intensity over a three-month timeframe in the mini-calendars provided.

Simply mark the day a symptom occurs (using a symbol from the symptom sign list), when your period begins, and the days you have headache pain, along with an indication of the severity in the mini-calendars. When you've completed your chart, bring it to your doctor's appointment to discuss it.

What to do next:

Take our migraine quiz
View profiles of migraine sufferers
Learn about FROVA®

The most common side effects associated with the use of FROVA are dizziness, tiredness, feeling of tingling, hot flashes, headache (other than migraine headache), dry mouth, hot or cold sensation, pain in joints or bones, chest pain, and indigestion.

+ View references

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24(suppl 1):24-36; 138-149. Available at: http://216.25.100.131/ihscommon/guidelines/pdfs/ihc_II_main_no_print.pdf. Accessed January 19, 2007.
2. American Council for Headache Education. Headache diary. Available at: http://www.achenet.org/resources/diary.php. Accessed February 21, 2007.
3. National Headache Foundation. Serotonin. Available at: http://www.headaches.org/consumer/topicsheets/serotonin.html. Accessed February 21, 2007.
4. American Council for Headache Education. Women and headaches. Available at: http://www.achenet.org/news/women.php. Accessed February 21, 2007.
5. American Council for Headache Education. Migraine and coexisting conditions. Available at: http://www.achenet.org/news/macc.php. Accessed February 21, 2007.
6. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the Depo-Estradiol challenge test. Headache. 1996;36:367-371.
7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354-361.
8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
9. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385-389.
10. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
11. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707-716.
12. Couturier EGM, Bomhof MAM, Knuistingh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
13. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
14. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190-1201.
15. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(72):2154-2158. doi: 10.1212/01.wnl.0000233888.18228.19.
16. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
17. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55:754-762.
18. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Res Med Opin. 2004; 20(9):1465-1472. doi: 10.1185/030079904x2745.
19. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
20. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x.
21. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780. doi:10.1111/j.1526-4610.2006.00437.x.
22. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
23. FROVA® Patient Product Information. Chadds Ford, PA: Endo Pharmaceuticals; 2007.

 

Patient Product Information PDF  |  Full Prescribing Information PDF  |   Get Adobe® Reader®

Important Safety Information

For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.

Warning

You are now leaving the FROVA.com website and moving to an external website independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.

If you do not wish to leave this site, click Cancel. Click OK to continue.